Thrombotic cardiovascular (CV) diseases, including heart attack (MI), stroke and deep venous thrombosis (DVT), are the leading cause of death in developed countries. Using transcriptional profiling of platelets, we identified the S100 calcium-modulated protein family member MRP-14 (S100A9) as an acute MI gene. Case- control validation studies demonstrated that elevated plasma levels of MRP-8/14 complexes predict increased risk of future CV events. Studies using MRP-14-/- mice determined that MRP-8/14 broadly regulates vascular inflammation. However, a key unanswered question is whether MRP-8/14 participates directly in thrombosis. In a recent report (Wang et al. J Clin Invest 2014), we showed that the time to arterial thrombotic occlusion was prolonged markedly in MRP-14-/- mice. We observed that MRP-14 and MRP-8/14 are expressed in and secreted by platelets, and that thrombus formation is reduced in whole blood from MRP-14-/- mice. Infusion of WT platelets or purified MRP-14 into MRP-14-/- mice shortened the carotid artery occlusion time, indicating that platelet-derived MRP-14 directly regulates thrombosis. We next identified CD36 as the platelet membrane receptor for MRP-14. Importantly, while deficiency of MRP-14 is protective of thrombosis, it has no effect on multiple parameters of hemostasis. The central hypotheses of this project are that platelet MRP-14 regulates arterial and venous thrombosis in a CD36-dependent manner, that this interaction can be exploited to develop a safer anti-thrombotic agent (i.e., reduced bleeding risk), and that plasma MRP- 8/14 levels are genetically determined and modified by CV disease activity. We propose 3 specific aims. First, we will characterize the molecular domains responsible for MRP-14:CD36 binding and the downstream signaling that leads to platelet activation. Second, we will investigate the role of MRP-14 in venous thrombosis and in arterial thrombosis in the context of atherosclerosis. Third, major genetic, cellular, and CV disease activity determinants of plasma MRP-8/14 concentration will be explored in collaboration with the Genes and Blood Clotting Study. The MRP-14:CD36 interaction represents a novel target for treating cardiovascular disorders, including heart attack stroke, and DVT. The results of these studies will provide important insights to exploit this interaction to influence thrombosis, but not hemostasis (i.e., reduced bleeding risk).

Public Health Relevance

Thrombotic cardiovascular diseases, including heart attack (MI), stroke and deep venous thrombosis (DVT), are the leading cause of death in developed countries. This project will capitalize on our recent identification of a new pathway of thrombosis involving platelet MRP-14 and CD36 that does not affect hemostasis, thereby providing a target for safer anti-thrombotic therapeutics. We will characterize the molecular domains responsible for MRP-14:CD36 binding and the downstream signaling that leads to platelet activation, investigate the role of MRP-14 in venous thrombosis and in arterial thrombosis in the context of atherosclerosis, and in clinical studies characterize the determinants of plasma MRP-8/14 concentration that predicts future cardiovascular risk.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL126645-01A1
Application #
9025295
Study Section
Hemostasis and Thrombosis Study Section (HT)
Program Officer
Chang, Henry
Project Start
2016-04-01
Project End
2020-03-31
Budget Start
2016-04-01
Budget End
2017-03-31
Support Year
1
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Stavrou, Evi X; Fang, Chao; Bane, Kara L et al. (2018) Factor XII and uPAR upregulate neutrophil functions to influence wound healing. J Clin Invest 128:944-959
Plow, Edward F; Wang, Yunmei; Simon, Daniel I (2018) The search for new antithrombotic mechanisms and therapies that may spare hemostasis. Blood 131:1899-1902
Zilberman-Rudenko, Jevgenia; Reitsma, St├ęphanie E; Puy, Cristina et al. (2018) Factor XII Activation Promotes Platelet Consumption in the Presence of Bacterial-Type Long-Chain Polyphosphate In Vitro and In Vivo. Arterioscler Thromb Vasc Biol 38:1748-1760
Maji, D; De La Fuente, M; Kucukal, E et al. (2018) Assessment of whole blood coagulation with a microfluidic dielectric sensor. J Thromb Haemost 16:2050-2056
Wang, Yunmei; Gao, Huiyun; Shi, Can et al. (2017) Leukocyte integrin Mac-1 regulates thrombosis via interaction with platelet GPIb?. Nat Commun 8:15559
Yang, Moua; Cooley, Brian C; Li, Wei et al. (2017) Platelet CD36 promotes thrombosis by activating redox sensor ERK5 in hyperlipidemic conditions. Blood 129:2917-2927
Sakuma, Masashi; Tanaka, Atsushi; Kotooka, Norihiko et al. (2017) Myeloid-related protein-8/14 in acute coronary syndrome. Int J Cardiol 249:25-31
Wang, Yunmei; Gao, Huiyun; Kessinger, Chase W et al. (2017) Myeloid-related protein-14 regulates deep vein thrombosis. JCI Insight 2:
Swindell, William R; Xing, Xianying; Fritz, Yi et al. (2016) Deficiency of myeloid-related proteins 8 and 14 (Mrp8/Mrp14) does not block inflammaging but prevents steatosis. Oncotarget 7:35535-35551
Schmaier, Alvin H (2016) Antithrombotic potential of the contact activation pathway. Curr Opin Hematol 23:445-52

Showing the most recent 10 out of 11 publications